New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.

@article{Schiff2014NewAT,
  title={New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis.},
  author={Michael H. Schiff and Jonathan S. Jaffe and Bruce Freundlich and Patrick Madsen},
  journal={Expert review of medical devices},
  year={2014},
  volume={11 5},
  pages={447-55}
}
Methotrexate (MTX) is the cornerstone of treatment for rheumatoid arthritis (RA), and is widely used both as first-line therapy and as an important component of long-term therapy. Although subcutaneous MTX is typically delivered orally, parenteral administration offers benefits with respect to tolerability and systemic exposure, and may be an underutilized… CONTINUE READING